Monoclonal antibody-based genetic immunotherapy

Current Gene Therapy

Volumn 4, Issue 3, 2004, Pages 347-356

  Pelegrin, Mireia ^a   Gros, Laurent ^a   Dreja, Hanna ^a   Piechaczyk, Marc ^a  

^a CNRS   (France)

Author keywords

Autoimmune diseases; Cancer; Cell therapy; Gene therapy; Gene transfer; Immunotherapy; Monoclonal antibodies; Viral diseases

Indexed keywords

ABCIXIMAB; ALEMTUZUMAB; ANTHRACYCLINE DERIVATIVE; BASILIXIMAB; CELLULOSE SULFATE; CROFAB; DACLIZUMAB; GEMTUZUMAB OZOGAMICIN; HEPATITIS B ANTIBODY; HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IBRITUMOMAB TIUXETAN; INFLIXIMAB; LAMIVUDINE; MONOCLONAL ANTIBODY; OKT 3; PALIVIZUMAB; RITUXIMAB; SNAKE VENOM ANTISERUM; TRASTUZUMAB;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; BLOOD CLOTTING DISORDER; BREAST CANCER; CARDIOVASCULAR DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMA; CROHN DISEASE; DNA MODIFICATION; ENVENOMATION; GENE DELIVERY SYSTEM; HEPATITIS B; HEPATITIS C; HUMAN; KIDNEY GRAFT REJECTION; MIGRAINE; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CARCINOMA; REVIEW; RHEUMATOID ARTHRITIS; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; VIRUS INFECTION; VOMITING;

EID: 4243117023     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/1566523043346246     Document Type: Review

References (74)

1. Baba, T. W., Liska, V., Hofmann-Lehmann, R., Vlasak, J., Xu, W., Ayehunie, S., Cavacini, L. A., Posner, M. R., Katinger, H., Stiegler, G., Bernacky, B. J., Rizvi, T. A., Schmidt, R., Hill, L. R., Keeling, M. E., Lu, Y., Wright, J. E., Chou, T. C. and Ruprecht, R. M. (2000). Human neutralizing monoclonal antibodies of the IgGI subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med., 6: 200-6.
2. Bookman, M. A., Darcy, K. M., Clarke-Pearson, D., Boothby, R. A. and Horowitz I. R. (2003). Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol., 21: 283-90.
3. Borrebaeck, C. A. and Carlsson, R. (2001). Human therapeutic antibodies. Curr. Opin. Pharmacol., 1: 404-8.
4. Bruggemann, M. and Taussig M. J. (1997). Production of human antibody repertoires in transgenic mice. Curr. Opin. Biotechnol., 8: 455-458.
5. Burton, D. R. (1997). A vaccine for HIV type I: the antibody perspective. Proc. Natl. Acad. Sci. USA, 94: 10018-23.
6. Burton, D. R. and Montefiori, D. C. (1997). The antibody response in HIV-I infection [see comments]. AIDS. 11: S87-98.
7. Carter, P. (2001). Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer, 1: 118-29.
8. Chadd, H. E. and Chamow, S. M. (2001). Therapeutic antibody expression technology. Curr. Opin. Biotechnol., 12: 188-94.
9. Chester, K. A. and Hawkins, R. E. (1995). Clinical issues in antibody design. Trends Biotechnol., 13: 294-300.
10. Dautzenberg, H., Schuldt, U., Grasnick, G., Karle, P., Muller, P., Lohr, M., Pelegrin, M., Piechaczyk, M., Rombs, K. V., Gunzburg, W. H., Salmons, B. and Saller, R. M. (1999). Development of cellulose sulfate-based polyelectrolyte complex microcapsules for medical applications. Ann. N. Y. Acad. Sci., 875: 46-63.
11. Déglon, N., Heyd, B., Tan, S. A., Joseph, J. M., Zurn, A. D. and Aebischer, P. (1996). Central nervous system delivery of recombinant ciliary neurotrophiC factor by polymer encapsulated differentiated C2C12 myoblasts. Human Gene Ther., 7: 2135-2146.
12. Eren, R., Ilan, E., Nussbaum, O., Lubin, I, Terkieltaub, D., Arazi, Y., Ben-Moshe, O., Kitchinzky, A., Berr, S., Gopher, J., Zauberman, A., Galun, E., Shouval, D., Daudi, N., Eid, A., Jurim, O., Magnius, L. O., Hammas, B., Reisner, Y. and Dagan, S. (2000). Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees. Hepatology, 32: 588-96.
13. Frenken L. G., Hessing, J. G., Van den Hondel, C. A. and Verrips C. T. (1998). Recent advances in the large-scale production of antibody fragments using lower eukaryotic microorganisms. Res. Immunol., 149: 589-99.
14. Gauduin, M. C., Parren, P. W., Weir, R., Barbas, C. F., Burton, D. R. and Koup, R. A. (1997). Passive immunization with a human monoclonal antibody protects hu-PBL- SCID mice against challenge by primary isolates of HIV- 1. Nat. Med., 3: 1389-93.
15. Glennie, M. J. and Johnson, P. W. (2000). Clinical trials of antibody therapy. Immunol. Today, 21: 403-10.
16. Grillo-Lopez, A. (2002). Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev Anticancer Ther., 2: 485-493.
17. Gruber, R., van Haarlem, L. J., Warnaar, S. O., Holz, E. and Riethmuller, G. (2000). The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A. Cancer Res., 60: 1921-6.
18. Gura, T. (2002). Therapeutic antibodies: magic bullets hit the target. Nature, 417: 584-6.
19. Hortelano, G., Al-Hendy, A., Ofosu, F. A. and Chang P. L. (1996). Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B. Blood. 87: 5095-103.
20. Horton, J. (2002). Trastuzumab use in breast cancer: clinical issues. Cancer Control, 9: 499-507.
21. Ilan, E., Arazi, J., Nussbaum, O., Zauberman, A., Eren, R., Lubin, I., Neville, L., Ben-Moshe, O., Kischitzky, A., Litchi, A., Margalit, I., Gopher, J., Mounir, S., Cai, W., Daudi, N, Eid, A., Jurim, O., Czerniak, A., Galun, E. and Dagan, S. (2002). The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV. J. Infect. Dis., 185: 153-61.
22. Ilan, E., Eren, R., Lubin, I., Nussbaum, O., Zauberman, A. and Dagan, S. (2002). The Trimera mouse: a system for generating human monoclonal antibodies and modeling human diseases. Curr. Opin. Mol. Ther., 4: 102-9.
23. Isaacs J. D. (1990). The antiimmunoglobulin response to therapeutic antibodies. Semin. Immunol., 2: 449-56.
24. Kaplan, J. M., Armentano, D., Sparer, T. E., Wynn, S. G., Peterson, P. A., Wadsworth, S. C., Couture, K. K., Pennington, S. E., St George, J. A., Gooding, L. R. and Smith, A. E. (1997). Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum. Gene Ther., 8: 45-56.
25. Kincade, P. W. and Gimble, J. M. (1993). B lymphocytes. In Fundamental Immunology Third Edition, W. E. Paul, ed., Raven Press, Ltd: New York, pp. 43-73.
26. Kuus-Reichel, K., Grauer, L. S., Karavodin, L. M., Knott, C., Krusemeier, M. and Kay, N. E. (1994). Will immunogenicity limit the use, efficacy and future development of therapeutic monoclonal antibodies? Clin. Diagn. Lab. Immunol., 1: 365-72.
27. Lewis, A. D., Chen, R., Montefiori, D. C., Johnson, P. R. and Clark, K. R. (2002). Generation of neutralizing activity against human immunodeficiency virus type I in serum by antibody gene transfer. J. Virol., 76: 8769-75.
28. Li, A., Katinger, H., Posner, M. R., Cavacini, L., Zolla-Pazner, S., Gorny, M. K., Sodroski, J., Chou, T. C., Baba, T. W. and Ruprecht, R. M. (1998). Synergistic neutralization of simian-human immunodeficiency virus SHIV- vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type I immunoglobulins. J. Virol., 72: 3235-40.
29. Lohr, M., Hoffmeyer, A., Kroger, J., Freund, M., Hain, J., Holle, A., Karle, P., Knofel, W., Liebe, S., Muller, P., Nizz, H., Renner, M., Sailer, R., Wagner, T., Hauenstein, K., Gunzburg, W. and Salmons, B. (2001). Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet, 357: 1591-1592.
30. Lowndes, S., Darby, A., Mead, G. and Lister, A. (2002). Steves-Johnson syndrome after treatment with rituximab. Ann. Oncol., 13: 1948-50.
31. Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M. and Lipsky, P. (1999). Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group [In Process Citation]. Lancet, 354: 1932-9.
32. Maloney, D. G., Grillo, L. A., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T. M., Dallaire, B. K., Wey, K., Royston, I., Davis, T. and Levy, R. (1997). IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 90: 2188-95.
33. Marks, C. and Marks, J. D. (1996). Phage libraries - a new route to clinically useful antibodies. New. Engl. J. Med., 335: 730-733.
34. Mascola, J. R., Lewis, M. G., Stiegler, G., Harris, D., VanCott, T. C., Hayes, D., Louder, M. K., Brown, C. R., Sapan, C. V., Frankel, S. S., Lu, Y., Robb, M. L., Katinger, H. and Birx, D. L. (1999). Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol., 73: 4009-18.
35. Mascola, J. R., Louder, M. K., VanCott, T. C., Sapan, C. V., Lambert, J. S., Muenz, L. R., Bunow, B., Birx, D. L. and Robb, M. L. (1997). Potent and synergistic neutralization of human immunodeficiency virus (HIV) type I primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J. Virol., 71: 7198-206.
36. Mascola, J. R., Stiegler, G., VanCott, T. C., Katinger, H., Carpenter, C. B., Hanson, C. E., Beary, H., Hayes, D., Frankel, S. S., Birx, D. L. and Lewis, M. G. (2000). Protection of macaques against vaginal transmission of a pathogenic HIV- I/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med., 6: 207-10.
37. McLaughlin, P., Grillo-Lopez, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., Jain, V., Ho, A. D., Lister, J., Wey, K., Shen, D. and Dallaire, B. K. (1998). Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol., 16: 2825-33.
38. Mendez, M. J., Green L. L., Corvalan, J. R. F., Jia, X. C., Maynard-Curie, C. A., Yang, X. D., Gallo, M. L., Louie, D. M., Lee, D. V., Erickson, K. L. Luna, J., Roy, C. M., Abderrahim, H., Kirschenbaum, F., Nogushi M., Smith, D. H.,, Fukushima, A., Hales, J. F., Finer, M. H., Zebo, C. G. D. K. M. and Jakobovitz, A. (1997). Functional transplant of megabase human immunoglobulin loci recapitulates human antibody in mice. Nature Genet., 15: 146-156.
39. Nabhan, C., Dyer, M. and Rosen, S. (2003). Current status of monoclonal antibody therapy for chronic lymphocytic leukemia. Oncology (Huntingt), 17: 253-62.
40. Nabhan, C. and Tallman, M. S. (2002). Early Phase I/II Trials with Gemtuzumab Ozogamicin (Mylotarg(R)) in Acute Myeloid Leukemia. Clin. Lymphoma, 2 Suppl. 1: S19-23.
41. Noel, D., Dazard J. E., Pelegrin, M., Jacquet, C. and Piechaczyk, M. (2002) Skin as a potential organ for ectopic monoclonal antibody production. J. Invest. Dermatol., 118: 288-94.
42. Noel, D., Pelegrin, M., Brockly, F., Lund, A. H. and Piechaczyk, M. (2000). Sustained systemic delivery of monoclonal antibodies by genetically modified skin fibroblasts. J. Invest. Dermatol., 115: 740-5.
43. Noel, D., Pelegrin, M., Kramer, S., Jacquet, C., Skander, N. and Piechaczyk, M. (2002). High in vivo production of a model monoclonal antibody on adenoviral gene transfer. Hum. Gene Ther., 13: 1483-93.
44. Noel, D., Pelegrin, M., Marin, M., Biard, P. M., Ourlin, J. C., Mani, J. C. and Piechaczyk, M. (1997). In vitro and in vivo secretion of cloned antibodies by genetically modified myogenic cells. Hum. Gene Ther., 8: 1219-29.
45. Okada, N., Miyamoto, H., Yoshioka, T., Sakamoto, K., Katsume, A., Saito, H., Nakagawa, S., Ohsugi, Y. and Mayumi, T. (1997). Immunological studies of SK2 hybridoma cells microencapsulated with alginate-poly(L)lysine-alginate (APA) membrane following allogeneic transplantation. Biochem. Biophys. Res. Commun., 230: 524-7.
46. Parren, P. W. and Burton, D. R. (2001). The antiviral activity of antibodies in vitro and in vivo. Adv. Immunol., 77: 195-262.
47. Pegram, M. D. and Slamon, D. J. (1999). Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin. Oncol., 26: 89-95.
48. Pelegrin, M., Bachrach, E. and Piechaczyk, M. (2003). Application of recombinant antibodies in gene trensfer and gene therapy. In Therapeutic antibody technology, T. Kieber-Emmons and Z. Steplewski, eds., Marcel Dekker, Inc.: New York, NY, pp. (in press).
49. Pelegrin, M., Marin, M., Noël, D., Del Rio, M., Sailer, R., Günzburg, W., Stange, S., Stefflen, M. and Piechaczyk, M. (1998 . Systemic long-term delivery of antibodies in immunocompetent animals using cellulose sulphate capsules containing antibody-producing cells. Gene Therapy, 5: 828-834.
50. Pelegrin, M., Marin, M., Noël, D. and Piechaczyk, M. (1998). Genetically engineered antibodies in gene transfer and gene therapy. Hum. Gene Ther., 9: 2165-2175.
51. Pelegrin, M., Marin, M., Oates, A., Noel, D., Sailer, R., Salmons, B. and Piechaczyk, M. (2000). Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies. Hum. Gene Ther., 11: 1407-15.
52. Piccioli, P., DiLuzio, A., Amann, R., Schuligoi, R., Surani, M. A., Donnerer, J. and Cattaneo, A. (1995). Neuroantibodies : ectopic expression of a recombinant anti-substance P antibody in the central nervous system of transgenic mice. Neuron, 15: 373-384.
53. Portis, J. L., Czub, S., Garon, C. F. and McAtee, F. J. (1990). Neurodegenerative disease induced by the wild mouse ecotropic retrovirus is markedly accelerated by long terminal repeat and gag-pol sequences from nondefective Friend murine leukemia virus. J. Virol., 64: 1648-56.
54. Rader, C. and Barbas, C. F. (1997). Phage display of combinatorial antibody libraries. Curr. Opin. Biotechnol., 8: 503-508.
55. Rehwald, U., Schulz, H., Reiser, M., Sieber, M., Staak, J. O., Morschhauser, F., Driessen, C., Rudiger, T., Muller-Hermelink, K., Diehl, V. and Engert, A. (2003). Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood, 101: 420-4.
56. Rose, N. R. and Bona, C. (1993). Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol. Today, 14: 426-430.
57. Rutgeerts, P. (2002). A critical assessment of new therapies in inflammatory bowel disease. J. Gastroenterol. Hepatol., 17 Suppl. S176-85.
58. Salmons, B., Lohr, M. and Gunzburg, W. (2003). Tratment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phaseI/II clinical trial. J Gastroenterol., 38: 78-84.
59. Sanhadji, K., Grave, L., Touraine, J. L., Leissner, P., Rouzioux, C., Firouzi, R., Kehrli, L., Tardy, J. C. and Mehtali, M. (2000). Gene transfer of anti-gp41 antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice. AIDS, 14: 2813-22.
60. Savelkoul, H. F., R., Vossen, A. C., Breedland, E. G., Coffman, R. L. and van Oudenaren, A. (1994). Modulation of systemic cytokine levels by implantation of alginate encapsulated cells. J. Immunol. Methods, 170: 185-96.
61. Schneider, J., Chang, A. and Garratt, A. (2002). Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study. Semin. Oncol., 29: 22-28.
62. Schneider, J., Chang, A. and Rocco, T. (2001). Cardiotoxicity in signal transduction therapeutics : erbB2 antibodies and the heart. Semin. Oncol., 28: 18-26.
63. Seiler, P., Kalinke, U., Rulicke, T., Bucher, E. M., Bose, C., Zinkernagel, R. M. and Hengartner, H. (1998). Enhanced virus clearance by early inducible lymphocytic choriomeningitis virus-neutralizing antibodies in immunoglobulin-transgenic mice. J. Virol., 72: 2253-8.
64. Shibata, R., Igarashi, T., Haigwood, N., Buckler-White, A., Ogert, R., Ross, W., Willey, R., Cho, M. W. and Martin, M. A. (1999). Neutralizing antibody directed against the HIV-I envelope glycoprotein can completely block HIV-I/SIV chimeric virus infections of macaque monkeys [see comments]. Nat. Med., 5: 204-10.
65. Stiegler, G., Armbruster, C., Vcelar, B., Stoiber, H., Kunert, R., Michael, N. L., Jagodzinski, L. L., Ammann, C., Jager, W., Jacobson, J., Vetter, N. and Katinger, H. (2002). Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS, 16: 2019-25.
66. Tai, I. T. and Sun, A. M. (1993). Microencapsulation of recombinant cells: a new delivery system for gene therapy. FASEB J., 7: 1061-9.
67. Taylor, P. C. (2003). Anti-TNFalpha therapy for rheumatoid arthritis: an update. Intern. Med., 42: 15-20.
68. Tripathy, S. K., Black, H. B., Goldwasser, E. and Leiden, J. M. (1996). Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat. Med., 2: 545-50.
69. van Nunen, A. B., de Man, R. A., Heijtink, R. A., Vossen, A. C. and Schalm, S. W. (2002). Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue? J Viral. Hepat., 9: 221-8.
70. Vaughan, T. J., Osbourn, J. K. and Tempest, P. R. (1998). Human antibodies by design. Nat. Biotechnol., 16: 535-9.
71. Wawrzynczak, E. J. (1995). Antibody therapy, Oxford, UK: BIOS Scientific Publishers Ltd.
72. Willemsen, R., Debets, R., Chames, P. and Bolhuis, R. (2003). Genetic engineering of T cell specificity for immunotherapy of cancer. Hum. Immunol., 64: 56-68.
73. Wright, A. and Morrison, S. L. (1997). Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol., 15: 26-32.
74. Zwick, M. B., Wang, M., Poignard, P., Stiegler, G., Katinger, H., Burton, D. R. and Parren, P. W. (2001). Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J. Virol., 75: 12198-208.